Abstract
Introduction
This report analyzes the emerging sector of molecular diagnostics. It provides
a clear classification, assessing the leading technologies and key tests which
are positioned in this exciting area of diagnostics. The current MDx market
size and leading players are analyzed, with a market forecast of the MDx
segment as well as the total in vitro diagnostic (IVD) market from 2007-13
also provided.
Scope
*A definitive classification system for in vitro diagnostics (IVD) and
molecular diagnostics (MDx), and the differing regulatory pathways in the
US/EU
*Market size and forecast growth rates to 2013 for IVD and MDx segments
*A detailed analysis of emerging ' companion diagnostics' (the synergy of
targeted prescription therapies with diagnostics)
*A database detailing c.120 MDx products on the market
Highlights
The MDx market is a small but fast growing segment of the global IVD market,
with an estimated 2007-13 CAGR of 14.0%. Total MDx sales are expected to
outpace the total IVD market (2007-13 CAGR of 5.0%) over the next six years
Of particular interest is the role of MDx in companion diagnostics (the
synergy between targeted prescription pharmaceuticals and molecular diagnostic
tests). Datamonitor has identified seven key therapeutics and more than 12 MDx
tests which exemplify this marriage
The report also details a MDx database containing more than 120 MDx tests. The
key tests are positioned in the therapy areas of infectious diseases,
hematology and oncology by key MDx players such as Roche Diagnostics,
Gen-Probe, Abbott Molecular and Myriad
Reasons to Purchase
*Compare the differing growth dynamics of the MDx segment and that of the
wider IVD market
*Assess the potential of ' companion diagnostics' and its role in influencing
physician selection of molecular targeted therapies
*Identify the key diagnostic tests and players in the MDx segment
| 
View Cart
